Stay informed with the latest litigation news. Explore now
Tablets Comprising Glp-1 Agonist And Enteric Coating - EP3250191B1
EP3250191
- Application Number
- EP16701684A
- Filing Date
- Jan 28, 2016
- Status
- Granted And Under Opposition
- Dec 15, 2023
- Grant Date
- Jan 17, 2024
- External Links
- Slate, Register, Google Patents
- Similar Patents facing opposition
Bibliography
The patent EP3250191B1 was granted to Novo Nordisk on Jan 17, 2024 following the initial filing on Jan 28, 2016 under the application number EP16701684A . The current legal status of the patent is Granted And Under Opposition.
Patent Summary
Patent Family New
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Get instant alerts for new documents